Clinical Trial Detail

NCT ID NCT03317496
Title Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Pfizer
Indications

non-small cell lung carcinoma

transitional cell carcinoma

urethra transitional cell carcinoma

Advanced Solid Tumor

ureter transitional cell carcinoma

renal pelvis transitional cell carcinoma

Therapies

Avelumab + Cisplatin + Gemcitabine

Avelumab + Carboplatin + Pemetrexed

Age Groups: adult senior

Additional content available in CKB BOOST